Clinical Trial Update: A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating low-dose sulindac combined with eflornithine for Familial Adenomatous Polyposis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Adenomatous Polyposis

Drugs mentioned

• Eflornithine (eflornithine)
• Sulindac (sulindac)

Snippet

Sponsor: Cancer Prevention Pharmaceuticals, Inc. | Conditions: Familial Adenomatous Polyposis | Phase 3 | Status: WITHDRAWN